Peel Hunt Reiterates Buy Rating for Silence Therapeutics (SLN)

Peel Hunt reaffirmed their buy rating on shares of Silence Therapeutics (LON:SLN) in a research report report published on Monday morning. They currently have a GBX 276 ($3.74) target price on the stock.

Silence Therapeutics (LON SLN) opened at GBX 198 ($2.69) on Monday. The firm has a market cap of $138.72 and a price-to-earnings ratio of -1,523.08. Silence Therapeutics has a 52-week low of GBX 71.88 ($0.97) and a 52-week high of GBX 254.75 ($3.45).

WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at

Silence Therapeutics Company Profile

Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company’s technology harnesses the body’s natural mechanisms to create therapeutic effects within its own cells.

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit